



Gong Mengchun, M.D.

Email: gmc@nrdrs.org

Mobile: +86 18611768672

Graduated from Peking Union Medical College with an M.D. degree, Dr. Gong Mengchun entered Peking Union Medical College Hospital and accomplished the internal residency training in 2014, after which time he worked in University of California, San Francisco as a visiting scholar.

Dr. Gong joined the area of applied medical informatics since 2015 and now works as the Distinguished Professor in the Institute of Health Management, Southern Medical University, China. He is actively engaged with international academic societies and holds the positions including the Management Board Director of SNOMED International (www.snomed.org), the Diagnostic Science Committee member of IRDiRC (www.irdirc.org), the Member-at-Large of the Global Health Informatics Workgroup of AMIA (www.amia.org), the Medical Informatics Consultant of the National Children's Care Center/Fudan University Children's Hospital and the member of the executive committee of the Chinese Association of Bioinformatics.

Dr. Gong took charge of the National Rare Diseases Registry System of China (www.nrdrs.org.cn) as the executive director from 2016 to 2019 and has been a pioneer in rare disease research and patient advocacy in China. His research focus covers medical terminology/ontology, precision medical informatics, rare diseases and orphan drugs development and health technology assessment (HTA). He is also actively engaged with the bioinformatics society in China and is currently a member of the executive committee of the Chinese Association of Bioinformatics. The paper *Cloud-Based System for Effective Surveillance and Control of COVID-19: Useful Experience from Hubei, China*, published in JMIR in April 2020, was selected as the best paper of the year by the International Medical Informatics Association (IMIA). Related digital hybrid surveillance system built during COVID-19 pandemic won WHO western-Pacific Innovation Challenge.

On the industrial side, as one of the co-founders, Dr. Gong holds the position of the Senior Vice President and Chief Medical Informatics Officer of Digital Health China Technologies Co. which is the leading company in China in precision medicine IT solution, healthcare big data and real-world insights.

Main Publications:

Liang L, Hu J, Sun G, Hong N, Wu G, He Y, Li Y, Hao T, Liu L, **Gong M**. Artificial Intelligence-Based Pharmacovigilance in the Setting of Limited Resources. *Drug Saf.* 2022 May;45(5):511-519. doi: 10.1007/s40264-022-01170-7. Epub 2022 May 17. PMID: 35579814; PMCID: PMC9112260. [IF=5.606]

Gong MC, Liu L, Sun X, Yang Y, Wang S, Zhu H. Cloud-Based System for Effective Surveillance and Control of COVID-19: Useful Experiences From Hubei, China. *J Med Internet Res.* 2020;22(4):e18948. doi:10.2196/18948 [IF=5.03]

Gong MC, Wang S, Wang L, et al. Evaluation of Privacy Risks of Patients' Data in China: Case Study. *JMIR Med Inform.* 2020;8(2):e13046. Published 2020 Feb 5. doi:10.2196/13046 [IF=3.19]

Wang HR, **Gong MC**, Sun JY, Sun J, Guo Y, Liu L, Zhu H. A new model for COVID-19 control and its implementation in the city of Honghu, China: a case report. *Antimicrob Resist Infect Control.* 2021 Feb 25;10(1):42. doi: 10.1186/s13756-021-00899-7. PMID: 33632318; PMCID: PMC7906241.

Liu P, **Gong MC**, Li J, Baynam G, Zhu W, Zhu Y, Chen L, Gu W and Zhang S (2021) Innovation in Informatics to Improve Clinical Care and Drug Accessibility for Rare Diseases in China. *Front. Pharmacol.* 12:719415. doi: 10.3389/fphar.2021.719415 (IF=5.8)

Xiao LS, Zhang WF, **Gong MC**, et al. Development and validation of the HNC-LL score for predicting the severity of coronavirus disease 2019. *EBioMedicine.* 2020;57:102880. doi:10.1016/j.ebiom.2020.102880 [IF=5.74]

Zhang YP, Xiao LS, Li P, Zhu HB, Hu CY, Zhang WF, Sun QC, Shen MY, Liu SS, Zhang WL, Zeng HY, **Gong MC**, Liu L, He YL, Zhu H*. Clinical characteristics of patients with progressive and non-progressive coronavirus disease 2019: evidence from 365 hospitalised patients in Honghu and Nanchang, China. *Frontiers in Medicine*, 2020. (IF=3.915)

Wang HR, **Gong MC**, Sun JY, Sun J, Guo Y, Liu L, Zhu H. A new model for COVID-19 control and its implementation in the city of Honghu, China: a case report. *Antimicrob Resist Infect Control.* 2021 Feb 25;10(1):42. doi: 10.1186/s13756-021-00899-7. [IF=3.68]

Su L, Liu C, Li D, et al. Toward Optimal Heparin Dosing by Comparing Multiple Machine Learning Methods: Retrospective Study. *JMIR Med Inform.* 2020;8(6):e17648. Published 2020 Jun 22. doi:10.2196/17648 [IF=3.19]

Baynam GS, Groft S, van der Westhuizen FH, et al. A call for global action for rare diseases in Africa. *Nat Genet.* 2020;52(1):21–26. doi:10.1038/s41588-019-0552-2 [IF=27.1]

Tan EH, Sena AG, Prats-Urbe A, You SC, Ahmed WU, Kostka K, Reich C, Duvall SL, Lynch KE, Matheny ME, Duarte-Salles T, Bertolin SF, Hripcsak G, Natarajan K, Falconer T, Spotnitz M, Ostropolets A, Blacketer C, Alshammari TM, Alghoul H, Alser O, Lane JCE, Dawoud DM, Shah K, Yang Y, Zhang L, Areia C, Golozar A, Recalde M, Casajust P, Jonnagaddala J, Subbian V, Vizcaya D, Lai LYH, Nyberg F, Morales DR, Posada JD, Shah NH, **Gong M**, Vivekanantham A, Abend A,

Minty EP, Suchard M, Rijnbeek P, Ryan PB, Prieto-Alhambra D. COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries. *Rheumatology (Oxford)*. 2021 Mar 16;keab250. doi:10.1093/rheumatology/keab250. Epub ahead of print. PMID: 33725121. [IF=5.6]

Feng S, Liu S, Zhu C, **Gong M**, Zhu Y, Zhang S. National Rare Diseases Registry System of China and Related Cohort Studies: Vision and Roadmap. *Hum Gene Ther*. 2018;29(2):128–135. doi:10.1089/hum.2017.215 [IF=3.85]

Zheng K, **Gong M**, Qin Y, et al. Validation of glomerular filtration rate-estimating equations in Chinese children. *PLoS One*. 2017;12(7):e0180565. Published 2017 Jul 6. doi:10.1371/journal.pone.0180565 [IF=2.78]

Qiu L, Guo X, Zhu Y, et al. Effect of picric acid and enzymatic creatinine on the efficiency of the glomerular filtration rate predictor formula. *Clin Lab*. 2013;59(5-6):511–522. doi:10.7754/clin.lab.2012.120524 [IF=1.2]

Cao Y, **Gong M**, Han Y, et al. Prevalence and risk factors for chronic kidney disease among HIV-infected antiretroviral therapy-naïve patients in mainland China: a multicenter cross-sectional study. *Nephrology (Carlton)*. 2013;18(4):307–312. doi:10.1111/nep.12031[IF=1.9]